189 related articles for article (PubMed ID: 37053010)
1. Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma.
Zheng L; Zhu ZR; Sneh T; Zhang WT; Wang ZY; Wu GY; He W; Qi HG; Wang H; Wu XY; Fernández-García J; Abramovich I; Xu YZ; Zhang J; Gottlieb E
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37053010
[TBL] [Abstract][Full Text] [Related]
2. Reporting on FH-deficient renal cell carcinoma using circulating succinylated metabolites.
Bezwada D; Brugarolas J
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37259915
[TBL] [Abstract][Full Text] [Related]
3. A Rare Case of Synchronous Fumarate Hydratase-Deficient Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma With Fumarate Hydratase and von Hippel-Lindau Gene Mutations: A Clinicopathologic and Molecular Study.
Wen H; Zheng L; Zhang M; Pan X; Wang D; Qian J; Zhang X; Zhou Q; Chen N
Int J Surg Pathol; 2024 Jun; 32(4):810-816. PubMed ID: 37715637
[TBL] [Abstract][Full Text] [Related]
4. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
[TBL] [Abstract][Full Text] [Related]
5. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
[TBL] [Abstract][Full Text] [Related]
6. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
Bardella C; El-Bahrawy M; Frizzell N; Adam J; Ternette N; Hatipoglu E; Howarth K; O'Flaherty L; Roberts I; Turner G; Taylor J; Giaslakiotis K; Macaulay VM; Harris AL; Chandra A; Lehtonen HJ; Launonen V; Aaltonen LA; Pugh CW; Mihai R; Trudgian D; Kessler B; Baynes JW; Ratcliffe PJ; Tomlinson IP; Pollard PJ
J Pathol; 2011 Sep; 225(1):4-11. PubMed ID: 21630274
[TBL] [Abstract][Full Text] [Related]
7. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC.
Gupta S; Swanson AA; Chen YB; Lopez T; Milosevic D; Kipp BR; Leibovich BC; Thompson RH; Herrera-Hernandez L; Cheville JC; Jimenez RE
Hum Pathol; 2019 Sep; 91():114-122. PubMed ID: 31299266
[TBL] [Abstract][Full Text] [Related]
8. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
[TBL] [Abstract][Full Text] [Related]
9. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
10. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
[TBL] [Abstract][Full Text] [Related]
11. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
Smith SC; Sirohi D; Ohe C; McHugh JB; Hornick JL; Kalariya J; Karia S; Snape K; Hodgson SV; Cani AK; Hovelson D; Luthringer DJ; Martignoni G; Chen YB; Tomlins SA; Mehra R; Amin MB
Histopathology; 2017 Jul; 71(1):42-52. PubMed ID: 28165631
[TBL] [Abstract][Full Text] [Related]
12. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms.
Kuroda N; Tsutsui M; Iguchi M; Nobuoka E; Uehara T; Sonobe Y; Morinaga Y; Shibuya S; Oda W; Yanai H; Kawada C; Karashima T; Yamasaki I; Inoue K; Nagashima Y
Ann Diagn Pathol; 2020 Dec; 49():151599. PubMed ID: 32977234
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
14. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
[TBL] [Abstract][Full Text] [Related]
15. AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Zheng L; Zhang X; Pan X; Huang Z; Zhang M; Xian J; Wei Y; Nie L; Zhang M; Gong J; Chen X; Zhou Q; Zeng H; Chen N
Mod Pathol; 2023 Nov; 36(11):100303. PubMed ID: 37580017
[TBL] [Abstract][Full Text] [Related]
16. Multidetector CT Characteristics of Fumarate Hydratase-Deficient Renal Cell Carcinoma and Papillary Type II Renal Cell Carcinoma.
Yang L; Li XM; Hu YJ; Zhang MN; Yao J; Song B
Korean J Radiol; 2021 Dec; 22(12):1996-2005. PubMed ID: 34668351
[TBL] [Abstract][Full Text] [Related]
17. Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas.
Yoo A; Tang C; Zucker M; Fitzgerald K; DiNatale RG; Rappold PM; Weiss K; Freeman B; Lee CH; Schultz N; Motzer R; Russo P; Coleman J; Reuter VE; Chen YB; Carlo MI; Gill AJ; Kotecha RR; Ari Hakimi A; Reznik E
Eur Urol Focus; 2022 Sep; 8(5):1278-1288. PubMed ID: 35288096
[TBL] [Abstract][Full Text] [Related]
18. Low-grade Oncocytic Fumarate Hydratase-deficient Renal Cell Carcinoma: An Update on Biologic Potential, Morphologic Spectrum, and Differential Diagnosis With Other Low-grade Oncocytic Tumors.
Hamza A; Sirohi D; Smith SC; Amin MB
Adv Anat Pathol; 2021 Nov; 28(6):396-407. PubMed ID: 34561376
[TBL] [Abstract][Full Text] [Related]
19. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases.
Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O
Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557
[TBL] [Abstract][Full Text] [Related]
20. Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma.
Liang J; Sun G; Pan X; Zhang M; Shen P; Zhu S; Zhao J; Zheng L; Zhao J; Chen Y; Yin X; Chen J; Hu X; Zeng Y; Chen J; Wang Y; Liu Z; Yao J; Su M; Huang R; Liao B; Wei Q; Li X; Zhou Q; Liu J; Shen Y; Liu Z; Chen N; Zeng H; Zhang X
Genome Med; 2023 May; 15(1):31. PubMed ID: 37131267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
